GSK Enlists Local Aid for Chinese Rollout of Hep B Drug

Why It Matters

China represents the world’s largest hepatitis B patient pool, so a rapid rollout could unlock a multi‑billion‑dollar market and accelerate GSK’s revenue growth while addressing a critical public‑health need.

Key Takeaways

• GSK partners with Sino Biopharm's CTTQ for Chinese bepirovirsen launch
• 75 million Chinese have chronic hepatitis B, key market share
• CTTQ handles import, distribution, hospital access for 5.5 years
• GSK retains licence, regulatory, and global medical strategy
• Projected peak sales $2.75 billion, boosting GSK's revenue target

Pulse Analysis

China’s chronic hepatitis B burden—estimated at 75 million adults—makes it the single largest market for any HBV therapy. GSK’s bepirovirsen, an antisense oligonucleotide co‑developed with Ionis, has earned breakthrough designation and priority review from the National Medical Products Administration. By securing a partnership with Sino Biopharm’s CTTQ, GSK taps a distribution network that spans over 5,000 hospitals, dramatically shortening the time needed to reach patients once regulatory clearance is granted.

The alliance goes beyond logistics. CTTQ will manage importation, supply chain, and promotional activities, while GSK retains the licence and oversees regulatory compliance, pharmacovigilance, and global medical strategy. In return, GSK receives an option on Sino Biopharm’s early‑stage pipeline, which includes four clinical‑stage HBV candidates such as TLR‑7/8 agonists, a capsid assembly modulator, and an siRNA therapy. This cross‑border pipeline access could give GSK a foothold in emerging Chinese innovations, potentially expanding its HBV portfolio beyond bepirovirsen.

Analysts estimate the HBV cure market could mirror the peak of the hepatitis C market, which generated roughly $10 billion annually before patient numbers fell. GSK’s internal model projects bepirovirsen could achieve $2.75 billion in peak annual sales, contributing significantly toward its goal of exceeding £40 billion ($52 billion) in revenue by 2031. If the drug delivers the promised functional cure rates, it would not only boost GSK’s top line but also align with China’s 2025 health plan, positioning the company as a key player in the global fight against chronic liver disease.